Intellipharmaceutics International Inc. (IPCI) PT Set at $6.00 by Maxim Group
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) has been given a $6.00 price target by stock analysts at Maxim Group in a research report issued on Friday. The firm presently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 99.34% from the company’s previous close.
Other analysts have also issued reports about the company. Zacks Investment Research lowered Intellipharmaceutics International from a “buy” rating to a “hold” rating in a research note on Thursday, October 27th. Brean Capital set a $8.00 price objective on Intellipharmaceutics International and gave the company a “buy” rating in a research note on Monday, October 17th.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) opened at 3.00 on Friday. Intellipharmaceutics International has a 52 week low of $1.41 and a 52 week high of $3.35. The firm’s market capitalization is $86.89 million. The stock’s 50 day moving average price is $2.87 and its 200-day moving average price is $2.04.
WARNING: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/11/29/intellipharmaceutics-international-inc-ipci-pt-set-at-6-00-by-maxim-group.html.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC acquired a new position in Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International at the end of the most recent quarter. Institutional investors and hedge funds own 1.68% of the company’s stock.
Intellipharmaceutics International Company Profile
IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Stock Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related stocks with our FREE daily email newsletter.